Clare A Stokes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4347659/publications.pdf

Version: 2024-02-01

29 papers	703 citations	623734 14 h-index	552781 26 g-index
31 all docs	31 docs citations	31 times ranked	575 citing authors

#	Article	IF	Citations
1	Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity. PLoS ONE, 2015, 10, e0140907.	2.5	96
2	Looking below the surface of nicotinic acetylcholine receptors. Trends in Pharmacological Sciences, 2015, 36, 514-523.	8.7	76
3	Working with OpusXpress: Methods for high volume oocyte experiments. Methods, 2010, 51, 121-133.	3.8	64
4	The Structural Basis for GTS-21 Selectivity between Human and Rat Nicotinic Î±7 Receptors. Molecular Pharmacology, 2004, 66, 14-24.	2.3	54
5	Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain. British Journal of Pharmacology, 1999, 127, 1337-1348.	5.4	47
6	Critical Molecular Determinants of Î±7 Nicotinic Acetylcholine Receptor Allosteric Activation. Journal of Biological Chemistry, 2016, 291, 5049-5067.	3.4	43
7	The Activity of GAT107, an Allosteric Activator and Positive Modulator of Î±7 Nicotinic Acetylcholine Receptors (nAChR), Is Regulated by Aromatic Amino Acids That Span the Subunit Interface. Journal of Biological Chemistry, 2014, 289, 4515-4531.	3.4	36
8	Persistent activation of Î±7 nicotinic ACh receptors associated with stable induction of different desensitized states. British Journal of Pharmacology, 2018, 175, 1838-1854.	5.4	31
9	Cysteine accessibility analysis of the human alpha7 nicotinic acetylcholine receptor ligand-binding domain identifies L119 as a gatekeeper. Neuropharmacology, 2011, 60, 159-171.	4.1	26
10	Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds. Nicotine and Tobacco Research, 2019, 21, 805-812.	2.6	25
11	Allosteric Agonism of Î±7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site. Molecular Pharmacology, 2019, 95, 606-614.	2.3	24
12	Macroscopic and Microscopic Activation of Î±7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. Molecular Pharmacology, 2019, 95, 43-61.	2.3	21
13	The Antinociceptive and Anti-Inflammatory Properties of the Î±7 nAChR Weak Partial Agonist p-CF₃N,N-diethyl-Nâ€²-phenylpiperazine. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 203-214.	2.5	17
14	Identification of Î±7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidineâ€”²â€isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation. ChemMedChem, 2017, 12, 1335-1348.	3.2	15
15	Synthesis, Pharmacological Characterization, and Structureâ€“Activity Relationships of Noncanonical Selective Agonists for Î±7 nAChRs. Journal of Medicinal Chemistry, 2019, 62, 10376-10390.	6.4	12
16	Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation. European Journal of Medicinal Chemistry, 2020, 205, 112669.	5.5	12
17	Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of Î±7 nAChR. Molecular Pharmacology, 2020, 98, 292-302.	2.3	12
18	NS6740, an Î±7 nicotinic acetylcholine receptor silent agonist, disrupts hippocampal synaptic plasticity. Neuroscience Letters, 2018, 677, 6-13.	2.1	11

#	Article	IF	Citations
19	Comparison of the Anti-inflammatory Properties of Two Nicotinic Acetylcholine Receptor Ligands, Phosphocholine and pCF3-diEPP. Frontiers in Cellular Neuroscience, 2022, 16, 779081.	3.7	11
20	Sulfonium as a Surrogate for Ammonium: A New Î±7 Nicotinic Acetylcholine Receptor Partial Agonist with Desensitizing Activity. Journal of Medicinal Chemistry, 2017, 60, 7928-7934.	6.4	10
21	Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant Î² Subunits Acquire Sensitivity to Î±7-Selective Positive Allosteric Modulators. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 252-268.	2.5	10
22	Allosterically Potentiated Î±7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium. Molecular Pharmacology, 2020, 98, 695-709.	2.3	10
23	Nicotinic Acetylcholine Receptor Accessory Subunits Determine the Activity Profile of Epibatidine Derivatives. Molecular Pharmacology, 2020, 98, 328-342.	2.3	10
24	Selective Agonists and Antagonists of Î±9 Versus Î±7 Nicotinic Acetylcholine Receptors. ACS Chemical Neuroscience, 2022, 13, 624-637.	3.5	10
25	Novel 5-(quinuclidin-3-ylmethyl)-1,2,4-oxadiazoles to investigate the activation of the Î±7 nicotinic acetylcholine receptor subtype: Synthesis and electrophysiological evaluation. European Journal of Medicinal Chemistry, 2018, 160, 207-228.	5.5	9
26	The Allosteric Activation of Î±7 nAChR by Î±-Conotoxin MrIC Is Modified by Mutations at the Vestibular Site. Toxins, 2021, 13, 555.	3.4	5
27	Stable desensitization of Î±7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. European Journal of Pharmacology, 2021, 905, 174179.	3.5	4
28	Sulfonium Ligands of the Î±7 nAChR. Molecules, 2021, 26, 5643.	3.8	2
29	Structureâ€Activity Relationships of Selective Pyrimidine Agonists on Î±7â€nAChRs. FASEB Journal, 2019, 33, 667.9.	0.5	0